益生菌對氣喘與呼吸道發炎狀態之預防及療效評估

The study of immunomodulatory agent Lactobacillus rhamnosus on airway inflammation in a mouse asthma model

吳佳達(Chia-Ta Wu)

指導教授 ： 呂克桓 ； 柯俊良

中山醫學大學/醫學院/醫學研究所/碩士(2015年)

https://doi.org/10.6834/CSMU.2015.00086

摘要

近年來氣喘的發生率持續的快速增加，因此針對氣喘所做的研究也愈來愈多而治療過敏氣喘的新藥也不斷的被開發出來。而現今針對益生菌的研究發現，其似乎具有調節腸內微生物的平衡等免疫為環境之能力，且進而能相關的發炎反應。
本研究是使用BALB/c母鼠以雞卵蛋白 (chicken ovalbumin, OVA)誘發小鼠產生致敏的現象，實驗中在第1天至第3天及第14天進行OVA腹腔注射進行致敏作用並於第14、17、21、24及27天進行OVA鼻腔吸入動作，此動物實驗模式已建立完成。此外本研究將致敏小鼠隨機分為2組，一組將LGG(Lactobacillus rhamnosus GG)餵食於實驗進程第1天至第14天此組的意義為探究LGG對於氣喘疾病預防的效果，另一組則為實驗進程第14天至第27天餵食致敏小鼠LGG此組別則為探究LGG對於氣喘的治療效果。而在本研究的對照組則是以生理實鹽水進行並做為非致敏小鼠之對照。
根據研究結果顯示，致敏小鼠具有的明顯呼吸道發炎反應現象會經由前後給予口服LGG而受到抑制，且其他相關生化數值，如IgE、Th2細胞激素也能獲得有效抑制，而IFN-γ與TGF-β部分則有顯著增加。
藉由本研究結果可發現口服LGG對於OVA致敏呼吸道炎症可有預防及治療的效果，因此，口服LGG對於過敏性疾病/氣喘疾病，在未來臨床上可能做為輔助性治療或預防之藥物。

關鍵字

氣喘 ； Lactobacillus rhamnosus GG ； 益生菌 ； 呼吸道過度反應 ； IFN-γ

並列摘要

The incidence of asthma has increased substantially in the last two decades. New medication is developed rapidly in recent years to apply to allergic asthma, since lots of people have investigated about the issue. However, now existing drugs just offer partial relief of symptoms in such disease. The goal of feature is to understand the complicated mechanism of asthma, and develop more effective drugs for suppressing the inflammatory response in asthma. In present study, LGG to prevent or treatment allergy is a new concept, it could improve balance of intestinal microbial and regulate allergic patient with immune system in intestinal and then reduce inflammation response and promote mucosal tolerance. This study explored Lacpodacillus rhammosus GG (ATCC 53103) was provided by previously study suggests LGG have been shown to modulate the immune system. Moreover, LGG could stimulate Th1 cytokines, suppress Th2 inflammatory cytokines responses and reduce inflammation.
We examined the role of agent of edible golden needle mushroom extract FIP-fve in a mouse asthma model after allergen-induced chronic airway inflammation. Female BALB/c mice, after intraperitoneal ovalbumin (OVA) sensitization on days 1 to 3 and 14, received intranasal OVA on days 14, 17, 21, 24 and Days 27. The mouse asthma model with airway inflammation by airway mucus release and infiltration by eosinophils was set up. The sensitized mice were divided into 2 groups. One group, the sensitized mice will be fed with LGG on days1 to days14 meaning prevention. Another group, the sensitized mice will be fed with LGG on days14 to days27 meaning treatment. In this mouse asthma model, normal saline was used as a positive control. The non-sensitized mice were used as a negative control. Both pre- and post-treatment with LGG suppressed the airway hyper-responsiveness (AHR) to methacholine and significantly decreased the number of infiltrating inflammatory cells and Th2 cytokines in bronchoalveolar lavage fluid (BALF) and serum compared with the OVA sensitized mice. In addition, LGG reduced OVA-specific IgE levels in serum. Oral LGG decreased Matrix Metalloproteinase 9 (MMP9) expression in lung tissue and inhibited inflammatory cell infiltration.
LGG had an anti-inflammatory effect on OVA-induced airway inflammation and might be an additional or supplementary therapy for allergic airway diseases.

並列關鍵字

Asthma ； Lactobacillus rhamnosus GG ； probiotics ； IFN-γ

參考文獻

2. 黃璟隆, 從台灣地區過敏病的增加談衛生假說. 台灣兒童過敏氣喘及免疫學會, 2003. 4(2).

23. 徐世達. 嬰幼兒氣喘預防與處置的新觀念. 台灣氣喘衛教學會. 2010; 18:6.

24. 林宏融、呂克桓. 益生菌是否能阻止過敏兒發展成為氣喘? 台灣兒童過敏氣喘及免疫學會學會通訊. 2005; 6(2): 2.

26. 陳建甫、吳克恭. 益生菌在過敏性疾病的療效探討. 台灣兒童過敏氣喘及免疫學會. 2007; 8:3.

30. 徐世達. 益生菌在過敏性疾病的治療與預防中的應用. 台灣氣喘衛教學會. 2010; 18:5.